Gut bacteria boosts immunotherapy in Hard-to-Treat lung cancer?
NCT ID NCT06448572
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests a combination of a healthy gut bacteria (EXL01) and the immunotherapy drug nivolumab for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. About 21 participants will receive the combination to see if it can help control the cancer. The goal is to find a new option for patients who have run out of effective therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Lille
RECRUITINGLille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.